Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 1/20 | 0.54 |
| ▸ | ACACB | O00763 | 5/20 | 0.49 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.46 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.46 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.46 |
| ▸ | MCHR1 | Q99705 | 6/20 | 0.44 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.42 |
| ▸ | FPR2 | P25090 | 1/20 | 0.41 |
| ▸ | PROKR1 | Q8TCW9 | 1/20 | 0.41 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.41 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.41 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.41 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22527429 | 1.00 | KCNH2 (0.54) | KCNH2ACACBPTGS1SLC6A2SLC6A4 | |
| SCHEMBL2311795 | 1.00 | KCNH2 (0.54) | KCNH2ACACBPTGS1SLC6A2SLC6A4 | |
| SCHEMBL19809288 | 0.89 | KCNH2 (0.47) | KCNH2ACACBPTGS1SLC6A2SLC6A4 | |
| SCHEMBL2357937 | 0.89 | KCNH2 (0.47) | KCNH2ACACBPTGS1SLC6A2SLC6A4 | |
| SCHEMBL19929308 | 0.89 | ACACB (0.48) | KCNH2ACACBFFAR1 | |
| SCHEMBL2364442 | 0.85 | KCNH2 (0.49) | KCNH2ACACBPTGS1SLC6A2SLC6A4 | |
| SCHEMBL2364439 | 0.85 | KCNH2 (0.49) | KCNH2ACACBPTGS1SLC6A2SLC6A4 | |
| SCHEMBL22527554 | 0.80 | KCNH2 (0.54) | KCNH2ACACBPTGS1SLC6A2SLC6A4 | |
| SCHEMBL22527383 | 0.80 | KCNH2 (0.56) | KCNH2ACACBPTGS1SLC6A2SLC6A4 | |
| SCHEMBL22527428 | 0.80 | KCNH2 (0.57) | KCNH2ACACBPTGS1SLC6A2SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113874341-B | Process for preparing derivatives of 1, 1-dialkylethane-1, 2-diols useful as intermediates | 科学与工业研究委员会 | 2024-05-31 | — | — | CN | disclosed |
| CN-113874341-A | Process for preparing derivatives of 1, 1-dialkylethane-1, 2-diols as useful intermediates | 科学与工业研究委员会 | 2021-12-31 | — | — | CN | disclosed |
| CN-107406386-B | Process for producing 1- (4-hydroxyphenyl) -4- (4-trifluoromethoxyphenoxy) piperidine or salt thereof | 大塚制药株式会社 | 2021-06-01 | — | — | CN | disclosed |
| WO-2020202205-A1 | PROCESS FOR THE PREPARATION OF DERIVATIVES OF 1,1-DIALKYLETHANE-1,2-DIOLS AS USEFUL INTERMEDIATES | COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) | 2020-10-08 | — | — | WO | disclosed |
| EP-3275862-B1 | METHOD FOR PRODUCING 1-(4-HYDROXYPHENYL)-4-(4-TRIFLUOROMETHOXYPHENOXY)PIPERIDINE OR SALT THEREOF | OTSUKA PHARMA CO LTD (JP) | 2020-08-12 | — | — | EP | disclosed |
| EP-3275862-B1 | METHOD FOR PRODUCING 1-(4-HYDROXYPHENYL)-4-(4-TRIFLUOROMETHOXYPHENOXY)PIPERIDINE OR SALT THEREOF | OTSUKA PHARMA CO LTD (JP) | 2020-08-12 | — | — | EP | disclosed |
| US-10252995-B2 | Method for producing 1-(4-hydroxyphenyl)-4-(4-trifluoromethoxyphenoxy)piperidine or salt thereof | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2019-04-09 | — | — | US | disclosed |
| EP-3275862-A1 | METHOD FOR PRODUCING 1-(4-HYDROXYPHENYL)-4-(4-TRIFLUOROMETHOXYPHENOXY)PIPERIDINE OR SALT THEREOF | Otsuka Pharmaceutical Co., Ltd. (JP) | 2018-01-31 | — | — | EP | disclosed |
| EP-2528896-B1 | SYNTHETIC INTERMEDIATE OF OXAZOLE COMPOUND AND METHOD FOR PRODUCING THE SAME | OTSUKA PHARMA CO LTD (JP) | 2014-08-27 | — | — | EP | disclosed |
| US-8598358-B2 | Synthetic intermediate of oxazole compound and method for producing the same | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2013-12-03 | — | — | US | disclosed |
| EP-2528896-A1 | SYNTHETIC INTERMEDIATE OF OXAZOLE COMPOUND AND METHOD FOR PRODUCING THE SAME | Otsuka Pharmaceutical Co., Ltd. (JP) | 2012-12-05 | — | — | EP | disclosed |
| US-20120302757-A1 | SYNTHETIC INTERMEDIATE OF OXAZOLE COMPOUND AND METHOD FOR PRODUCING THE SAME | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2012-11-29 | — | — | US | disclosed |
| WO-2011093529-A1 | SYNTHETIC INTERMEDIATE OF OXAZOLE COMPOUND AND METHOD FOR PRODUCING THE SAME | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2011-08-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120302757-A1 | SYNTHETIC INTERMEDIATE OF OXAZOLE COMPOUND AND METHOD FOR PRODUCING THE SAME | GLP1R, HBB, OXA1L | KCNH2 2417/4885ACACB 1750/4885PTGS1 3299/4885 |
| US-10252995-B2 | Method for producing 1-(4-hydroxyphenyl)-4-(4-trifluoromethoxyphenoxy)piperidine or salt thereof | DHPS, PAH, HPD | KCNH2 174/4885ACACB 3559/4885PTGS1 322/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.